Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Is Summit Therapeutics a Buy, Sell, or Hold Now? @themotleyfool #stocks $SMMT $AKES.F

Key PointsShares of Summit Therapeutics recently fell in response to differences measured between Asian and Western patients who received its experimental cancer treatment. Ivonescimab didn't provide a statistically significant overall survival benefit, but it was close.Despite a big stock price drop, expectations for future ivonescimab sales are high.10 stocks we like better than Summit Therapeutics › A rocky road for Summit Therapeutics got a …

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332In the North American patients, the OS HR was 0.70The HARMONi trial has already demonstrated clinically meaningful and statistically significant progression-free survival…

Summit Therapeutics hits possible snag on lung cancer drug seen as a blockbuster

The drug, ivonescimab, produced weaker results in patients from North America and Europe than those from China.

16.8-Month Survival Breakthrough: Summit's Novel Cancer Drug Shows Promise in Global Lung Cancer Trial

Summit's ivonescimab plus chemo achieved 16.8 months median OS vs 14.0 months in EGFRm NSCLC patients. North American results show HR=0.70, with consistent benefits across Western populations.